Abstract SF188/V? is a highly vascular human glioma model that is based on transfection of vascular endothelial growth factor (VEGF) cDNA into SF188/V-cells. This study aims to assess its growth and vascularity properties in vivo in a rat model. Thirty-two adult rats were inoculated with SF188/V? tumor cells, and, for comparison, five were inoculated with SF188/V-tumor cells. Several conventional magnetic resonance imaging (MRI) sequences were acquired, and several quantitative structural (T 2 and T 1 ), functional [isotropic apparent diffusion coefficient (ADC) and blood flow], and molecular [protein and peptide-based amide proton transfer (APT)] MRI parameters were mapped on a 4.7 T animal scanner. In rats inoculated with SF188/V? tumor cells, conventional T 2 -weighted images showed a highly heterogeneous tumor mass, and post-contrast T 1 -weighted images showed a heterogeneous, strong enhancement of the mass. There were moderate increases in T 2 , T 1 , and ADC, and large increases in blood flow and APT in the tumor, compared to contralateral brain tissue. Microscopic examination revealed prominent vascularity and hemorrhage in the VEGF-secreting xenografts as compared to controls, and immunohistochemical staining confirmed increased expression of VEGF in tumor xenografts. Our results indicate that the SF188/V? glioma model exhibits some MRI and histopathology features that closely resemble human glioblastoma.
Introduction
Glioblastoma (GBM) is the most common primary brain tumor in adults and accounts for more than 50 % of all gliomas. It is also the most deadly of the gliomas, with a median survival of 12-14 months [1] . Few patients are alive 5 years after diagnosis [2, 3] , even with maximal therapy, consisting of tumor resection, intensity-modulated radiation therapy (RT), temozolomide (TMZ), and the locally delivered 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) wafers (Gliadel) [4] . GBM is a highly vascularized tumor, notorious for irregular blood vessels, extensive vascular proliferation, and increased expression of angiogenic factors, most notably the vascular endothelial growth factor (VEGF). The high expression of VEGF on tumor endothelium, correlated with tumor hypoxia [5] , results in growth and proliferation of endothelial cells, areas of necrosis, and overall poor prognosis [6] .
Recognizing the critical need for new approaches to improve the outcome for patients with GBM has resulted in numerous pre-clinical studies. However, evaluation of new therapeutic strategies requires an accurate animal model, which mirrors as closely as possible the imaging, pathological, and clinical features of the human disease. Rodent glioma models are commonly used in the neuro-oncology field [7, 8] . However, the majority of these models lack important pathological features when compared to human GBM [9, 10] . SF188/V? is a human glioma model that is based on transfection of VEGF cDNA into SF188/V-cells [11] in order to produce an angiogenic cell line that expresses a high amount of VEGF. This vascular cell line has been used in pharmacokinetic (PK) studies to test the combination of cytotoxic and anti-angiogenesis compounds [12, 13] .
During the last 3 decades, magnetic resonance imaging (MRI) became a standard modality for neuroimaging. The most common MRI sequences used in the clinic include T 2 -weighted, fluid-attenuated inversion recovery, and gadolinium-enhanced T 1 -weighted images, which are used to determine the extent of tumor involvement and to assess tumor response to therapy [14] [15] [16] . In addition, there are several advanced imaging techniques, such as diffusion imaging to probe tumor cellularity [17] [18] [19] [20] , perfusion and blood volume imaging to detect the microvascular integrity [21, 22] , and proton MR spectroscopic imaging to determine metabolic status [23, 24] . Recently, a specific chemical exchange-based saturation transfer MRI technique [25] , dubbed amide proton transfer (APT) imaging [26] , was proposed, which can be used to detect over-expressed, endogenous mobile proteins and peptides (micromolarmillimolar range) in tumor [27] [28] [29] [30] .
The SF188/V? glioma model could potentially play an important role in angiogenesis research in the neuro-oncology field. To our knowledge, however, the MRI characteristics of SF188/V? tumor xenografts in vivo have not been reported until now. In this study, we characterize in vivo the growth and vascularity properties of the SF188/V? human glioma cell line in a rodent model using a multi-parameter MRI protocol, including conventional (structural), functional, and molecular MRI sequences.
Materials and methods

Cell lines
The SF188/V? and SF188/V-human glioma cell lines were kindly provided by Dr. Gallo (Temple University, Philadelphia, PA, USA; currently Mount Sinai School of Medicine, New York, NY, USA). The parental SF188/Vcell line was originally provided by the Brain Tumor Research Center, University of California, San Francisco, CA, USA. As described by Ma et al. [11] , mouse full-length VEGF164 cDNA (583 bp) was originally constructed in the Bluescript KS vector (Strategene) within BamHI and EcoRI sites of the vector. It was cloned into the PcDNA3 mammalian expression vector by standard methods. The VEGF sense plasmids contained the coding sequences for the sense VEGF164 under the transcription control of the CMV promoter. The sense VEGF164 cDNA was then transfected into SF188 cells (SF188/V?). Colonies were selected by G418 at a concentration of 800 mg/ml.
Prior to implantation, the SF188/V? and SF188/Vhuman glioma cell lines were grown in DMEM with Earle salts and L-glutamine (Mediatech), supplemented with 10 % fetal bovine serum (Gemini Bioproducts), 2 mmol/l sodium pyruvate (Mediatech), 0.1 mmol/l DMEM-nonessential amino acids (Mediatech), and gentamycin (Mediatech). The cells were grown at 37°C in a humidified incubator with 5 % CO 2 .
Tumor cell implantation
The study was approved by the Johns Hopkins Animal Care and Use Committee (ACUC), and all procedures were conducted in compliance with their regulations. Thirtyseven male, athymic rats (Harlan Bioproducts, Indianapolis, IN, USA) weighing 200-250 g were anesthetized by intraperitoneal injection of 3-5 ml/kg body weight of a stock solution, containing ketamine hydrochloride 25 mg/ml, xylazine 2.5 mg/ml, and 14.25 % ethyl alcohol in 0.9 % NaCl. Anesthetized animals were secured in a stereotactic apparatus. The scalp was cleaned, and a midline incision was made to expose the skull. A burr hole was drilled by an automatic drill, centered 3 mm to the left of the sagittal suture, avoiding the sagittal sinus, and 5 mm posterior to the coronal suture. A 25-ll Hamilton syringe with a 26-gauge needle attached to the stereotactic frame was used to inject either 1.5, 3, or 5 million SF188/V? cells (n = 14, 9, or 9, respectively) or 1.5 million SF188/V-cells (n = 5) in 5 ll sterile saline at a depth of 5 mm from the skull. The needle was then withdrawn, and the skin was closed with sutures. The rats were returned to their cages and received a regular rat diet and water ad libitum. The rats were monitored daily for weight loss and neurological deficit.
Animal care during MRI
On each of the experimental days indicated, animals implanted with tumor cells were re-anesthetized with 5 % isoflurane in a mixture of 75 % air and 25 % O 2 in a plexiglass container for about 5 min for induction, followed by breathing of 1.5-2.5 % isoflurane through a nose cone fixed with an MRI coil setup during MRI procedures. While anesthetized, a PE-10 catheter was placed into the dorsal tail vein to administer gadolinium contrast agents prior to MRI. The rat head and body were fixed and taped to the coil and cradle to avoid motion artifacts. Throughout the MRI procedure, rats were constantly monitored online through a small-animal respiratory-gating system connected with optic fibers, and the breathing rate of the animal was kept at 40 ± 5 breaths per minute by adjusting the isoflurane ratio (1.5-2.5 %) in the breathing mixture.
MRI experiments
MRI data were acquired using a horizontal bore 4.7 T animal MR imager (Bruker Biospin) with an actively decoupled cross-coil setup (a 70-mm body coil for radiofrequency transmission and a 25-mm surface coil for signal reception). Local shimming was performed on the brain. , and APT (frequency-labeling offsets of ±3.5 ppm; TR = 10 s; TE = 30 ms; saturation power = 1.3 lT; saturation time = 4 s; NA = 16). As described previously [27, 28] , these maps were obtained with single-shot, spin-echo, echo-planar imaging (EPI) data acquisition (matrix = 64 9 64; FOV = 32 9 32 mm 2 ; single-slice; slice thickness = 1.5 mm). The image slice was overlapped with one of the T 2 -weighted images. Finally, T 1 -weighted images (TR = 700 ms; TE = 10 ms; NA = 10) with and without gadolinium enhancement were acquired with the same geometry and location as the T 2 -weighted images. About 90 min were used to run all these experiments.
Data analysis
All data processing was performed using Interactive Data Language (IDL, Research Systems, Boulder, CO, USA). Data processing methods and procedures used were the same as our previous publications [27, 28] . Briefly, The T 1 map, T 2 map, and ADC map were fitted, using the following equations: I = A ? B exp(-TI/T 1 ), I = I 0 exp(-TE/T 2 ), and I = I 0 exp(-b ADC), respectively. The CBF map was reconstructed from images with and without labeling using previously described methods [31] . As described previously [27, 28] , the APT signal was calculated using the MTR asymmetry (MTR asym ) at the offset of 3.5 ppm with respect to water: MTR asym (3.5 ppm) = S sat (-3.5 ppm)/ S 0 -S sat (?3.5 ppm)/S 0 , where S sat and S 0 are the signal intensities with and without selective radiofrequency irradiation, respectively.
For the quantitative image analysis, we used the signal abnormalities on the high-resolution T 2 -weighted images and gadolinium-enhanced T 1 -weighted images, as well as APT images as a basis for defining regions of interest (ROIs). For all cases, the tumor ROIs covered most areas of the lesions with the signal abnormalities on MRI. For each rat, the same tumor region was analyzed for all MRI variables. Ventricles and peritumoral edema were excluded. We have previously demonstrated that novel APT imaging can separate the tumor from peritumoral edema and cerebrospinal fluid (hyperintensity vs. isointensity) [27] [28] [29] . The MRI parameter difference between ipsilateral and contralateral to the tumor side for all MRI measures was analyzed with a paired, two-tailed t test. The level of significance was set at P \ 0.05.
Histology
When rats were deeply anesthetized (breathing stopped), the animals were perfused with 75 ml sterile saline followed by 75 ml 4 % paraformaldehyde. After euthanasia, brains were excised and preserved in 4 % paraformaldehyde at 4°C for a week for proper tissue fixation. When the brains were sectioned, the acquired MR images and intrinsic landmarks, such as the corpus callosum and the ventricles, were used for reference. Next, 10-lm-thick cryostat sections were cut and processed for hematoxylin and eosin (H&E) staining for histopathological evaluation by a board-certified neuropathologist. Immunohistochemical analysis was performed using standard techniques with rabbit anti-VEGF (1:1,200, SC-152; Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Results
Radiographic features of tumor xenografts
Rats that were each inoculated with either 1.5, 3, or 5 million SF188/V? cells (n = 9 for each group) grew a tumor mass during the first 3 weeks post-implantation. These tumor masses became clearly visible (*1 mm) in MRI between 1 and 3 weeks after tumor inoculation, and then continued to grow. After the tumors formed, their morphological features became very similar, independent of the tumor cell number inoculated. In a second set of experiments comparing xenograft formation using cells with high or low levels of VEGF, the SF188/V-tumors grew at a slower rate than the SF188/V? xenografts (n = 5 for each group), which is consistent with a previous study [11] . Figure 1 shows one example of the longitudinal changes of SF188/V? tumor xenografts in rats on the T 2 -weighted MR images from 1 to 7 weeks post-implantation (5 million tumor cells implanted). In the initial 2 weeks postimplantation, a tiny T 2 -hypointense lesion was observed at the injection site. Then, a T 2 -hyperintense tumor mass started to form at 3 weeks post-implantation and grew rapidly from 3 to 5 weeks. Starting at 5 weeks postimplantation, the tumor became extremely heterogeneous on the T 2 -weighted images, possibly due to the acute or chronic hemorrhage [32] . The mass effect was apparent, as reflected by the displacement of the central structure. Hydrocephalus was also clearly observed. These effects became more exaggerated at the last MRI time point (7 weeks post-tumor inoculation), where the tumor occupied a large part of the left hemisphere. Figure 2 shows another example of the MR images of SF188/V? tumor xenografts in the rat brain at 2 weeks post-implantation (3 million tumor cells implanted). This SF188/V? tumor grew very fast. T 2 -weighted images showed a large lesion at 2 weeks post-implantation. The lesion was extremely heterogeneous, due to the acute or chronic hemorrhage. On the T 1 -weighted images (without contrast agents injected), the tumor was also very heterogeneous, with scattered punctate hyperintense foci, which indicated the hemosiderin deposition from the subacute hemorrhage. The gadolinium-enhanced T 1 -weighted images showed large heterogeneous enhancement in the tumor.
Quantitative results of tumor xenografts
Multi-parameter MR maps measured for an SF188/V? tumor at 2 weeks post-implantation (3 million tumor cells implanted; the same rat as Fig. 2 ) and an SF188/V-tumor at 2 weeks post-implantation (1.5 million tumor cells implanted) are shown in Fig. 3a, b , respectively. Unlike SF188/V?, the SF188/V-tumor demonstrates low or even no gadolinium enhancement on the post-contrast T 1 -weighted images. In the SF188/V? tumor model, as expected, T 2 , T 1 , ADC, blood flow, and APT were all hyperintense in the tumor region, compared to the contralateral brain tissue. The SF188/V? tumor shows much higher blood flow and APT-MRI signals that likely reflect hemorrhagic changes as compared to the SF188/V-tumor. Note that the heterogeneity of the tumor, observed on the T 2 -weighted and T 1 -weighted images, was slightly averaged on these low-resolution quantitative MR maps due to the partial volume effect.
The comparison of these quantitative MRI parameters for SF188/V? tumors (2-4 weeks post-implantation; n = 14) and the contralateral hemispheres is given in Table 1 . There were significantly higher MRI parameters (T 2 , T 1 , ADC, blood flow, and APT) in the tumor area than in the contralateral brain tissue (P \ 0.01 for blood flow; P \ 0.001 for the others). There were particularly high blood flow (1,247 ml/100 g/min) and APT (11.0 % of the bulk water intensity) signals in the SF188/V? tumor, compared to the contralateral brain tissue (117 ml/100 g/min and -1.8 %, respectively), as well as to other tumor models, such as 9L (85.3 ml/100 g/min [33] and 2.7 % [28] ) and U87MG (61.3 ml/100 g/min and 3.1 % [28] ). The high blood flow in the SF188/V? tumor xenografts suggests intratumoral vascular changes such as neovascularization. The notable APT hyperintensity in SF188/V? may be due to a much higher concentration of mobile proteins and peptides, such as cytosolic proteins and secreted proteins (serum albumin).
Histology
Microscopic examination of H&E-stained brain sections revealed changes consistent with the imaging characteristics (Fig. 4) . In xenografts generated from cells expressing either high (SF188/V?) or low (SF188/V-) levels of VEGF in which animals were sacrificed after 2 weeks, vascular dilatation and associated hemorrhage were prominent in the lesions expressing the angiogenesis factor. Interestingly, dilatation and hemorrhage were noted in vascular elements in the host brain adjacent to tumor xenografts, suggesting the VEGF secreted by the tumor could diffuse and affect blood vessel biology at some distance from the main neoplastic mass. In contrast, almost no large, dilated vessels were noted in the SF188/V-xenograft. Intracranial SF188/V? tumors removed after 4 weeks of growth were larger but had similar vascular changes. The cellular tumor xenografts contained numerous mitotic figures and apoptotic bodies as well as scattered blood vessels, many of which were extremely dilated. Some intravascular thrombosis was noted, along with extravascular hemorrhage. In some xenografts, a network of smaller vessels was also prominent, and some tightly packed tumor nodules had emerged. To confirm the increased expression of VEGF in SF188/V? cells growing in vivo, we stained xenografts for VEGF using standard immunohistochemical techniques. Moderate to high VEGF staining was noted in and around vessels of SF188/V? cells, while only weak staining was noted in the SF188/V-xenograft.
Discussion
The understanding that angiogenesis is crucial to tumor growth and progression has led to numerous pre-clinical studies [34] and clinical trials [35] testing the efficacy of anti-angiogenic therapy in the last 2 decades. These pre- clinical studies have mostly been facilitated through the use of animal tumor models. However, there is currently no widely accepted glioma model that can closely mirror human GBM growth patterns. The 9L, F98, U87, U251, and many other cell lines are commonly used as glioma models, and to date have provided important information regarding glioma biology and therapy [7, 8] . However, it is known that each of these established glioma models has limitations. For example, 9L and F98 are not derived from human tumors; thus, they may have a different response, as compared to human gliomas. Although intratumoral hemorrhage is often encountered in human GBM, it is less common in most established tumor models, including U87 human tumor xenografts [10] . Further, as opposed to the highly heterogeneous, infiltrative pattern of the human disease, 9L, F98, U87, and U251 all have relatively homogenous, well-defined growth patterns with sharply demarcated tumor margins ( Supplementary Fig. 1 ). The transfection of VEGF cDNA into SF188/V-cells results in the SF188/V? cell line that produces a high amount of VEGF [11] . Inoculating these cells in athymic rats produces tumor xenografts with prominent vascularity and hemorrhages, as reflected by particularly high blood flow and APT signals ( Fig. 3 ; Table 1 ). The SF188/V? tumor xenografts show scattered punctate hyperintense foci on the T 1 -weighted images without contrast agents injected (Fig. 2) . This important clinical feature likely reflects hemorrhagic changes, which are rarely observed in many established glioma models, such as 9L, F98, U87, and U251, as well as SF188/V-. The SF188/V? glioma shows an extremely heterogeneous signal on the T 2 -weighted images and a heterogeneous enhancement on the postcontrast T 1 -weighted images (Figs. 1, 2) . The presence of these key imaging and histopathology features of human GBM shows that SF188/V? would be particularly beneficial for testing GBM response to anti-angiogenesis drugs.
Despite its advantages, the SF188/V? glioma model has some limitations. First, in six athymic rats from our study, five inoculated with 5 million tumor cells and one inoculated with 3 million cells, the tumors started to shrink 4-5 weeks after formation and disappeared eventually ( Supplementary Fig. 2 ). Despite the limitation, this model has morphological and vascularity characteristics that are similar to human GBM, and has the potential to be adapted to testing anti-angiogenesis agents. However, care should be taken when using this intracranial xenograft model, and the implanted tumor xenografts should be assessed using imaging modalities such as MRI, which would allow noninvasive, longitudinal, and real-time monitoring of tumor growth and shrinking.
While the heterogeneous nature of GBM is well mimicked on imaging, molecular heterogeneity is circumvented by artificially overexpressing VEGF in all cells. This should be taken into account when interpreting and transferring the results obtained through this model to a clinical setting. A final limitation is the lack of significant infiltration of SF188/V? glioma cells into the surrounding brain parenchyma. However, while further efforts towards developing a model completely mimicking the pathological, molecular, and radiographic characteristics of human GBM are still needed, the data presented here suggest that several key vascular features of these aggressive tumors are recapitulated by SF188/V? cells, and these can be tracked using advanced imaging techniques.
Conclusions
In this study, we have investigated the imaging features and progression of SF188/V? human glioma in a rat model. MRI demonstrated that the tumors had highly heterogeneous signals on the T 2 -weighted images and a heterogeneous enhancement on the gadolinium-enhanced T 1 -weighted images. Very large blood flow and APT signals were observed in the tumor, compared to contralateral brain tissue. These results clearly reflect the unique morphological and vascularity characteristics of the SF188/V? glioma model that are potentially important for pre-clinical studies of anti-angiogenic therapy.
